INTRODUCTION
Active Heymann Nephritis is an autoimmune glomerular disease and has served as an important model for the study of membranous glomerulonephropathy, a common glomerular disease in humans. Morphologically, the disease is characterized by the formation of glomerular immune-deposits which ultrastructurally appear electron-dense and are exclusively located in the sub-epithelial region of glomerular basement membrane. On direct immunofluorescence the deposits stain for IgG and complement, and give a characteristic fine to coarse granular appearance outlining the glomerular capillaries. The dominant autoantigen (gp330) of active Heymann Nephritis, a single polypeptide receptor involved in endocytosis, was first recognized by us as a mannose-or glucose-containing renal glycoprotein (Makker, 1979 (Makker, , 1980 , with molecular mass approx. 600 kDa Singh, 1982, 1984) . The primary structure of fragments of gp330 was reported by Raychowdhury et al. (1989) and revealed similarity to epidermal-growth-factor precursor (EGFp), low-density-lipoprotein (LDL) receptor (LDLr) (Yamamoto et al., 1984) and LDLr-related protein (LRP)/a2-macroglobulin receptor (Herz et al. 1988; Strickland et al., 1990; Kristensen et al., 1990) . Immunohistochemical studies with a polyclonal antibody to a C-terminal peptide and a monoclonal antibody to gp330 have lead to a proposal that there may be two forms of gp330 on the cell surface (Bachinsky et al., 1993) . In this paper we report the sequence of 1650 amino acid residues of the C-terminal end of gp330 and compare this sequence with the sequence of fragments of gp330 reported previously by Raychowdhury et al. (1989) . The comparison provides direct evidence for the existence of two molecular forms of gp330 differing in their primary structure.
MATERIALS AND METHODS gp330 clone 3A was obtained by immunoscreening of a rat kidney lgtl 1 expression library (Clontech, Palo Alto, CA, U.S.A.) with a monospecific polyclonal antibody prepared against homogeneous rat gp330 by using standard protocols (Sambrook et al., 1989) . Preparations of gp330 protein from rat kidney and of polyclonal antibody to gp330 have been described previously (Kanalas and Makker, 1993) . Clones TA9, TA28 and 2E were obtained by 5' RACE (Rapid Amplification of cDNA Ends) procedure by PCR using appropriate oligonucleotide primers. 5' RACE (Frohman et al., 1988) was performed using a commercial kit (Gibco-BRL) according to instructions from the supplier. Sequencing was performed by the dideoxy method (Sanger et al., 1977) using Sequenase (USB-Amersham).
RESULTS AND DISCUSSION
The map of cloned cDNAs is shown in Figure 1 , and the deduced amino acid sequence is shown in Figure 2 . The amino acid sequence of the clones encompassing the C-terminal part of Figure 1 . The membranespanning domain consists of 22 amino acid residues (Figure 2 ) and separates the C-terminal cytoplasmic tail (213 amino acid residues long) from the extracellular domain. The organization of various repeats in gp330 (Figure 1 ) and LRP in C-terminal parts is similar. However, the number of EGFp-like repeats adjacent to the membrane spanning domain is fewer in gp330 (two'versus seven) (Herz et al., 1988) . In the region of non-repetitive similarity to LDLr and EGFp (amino acid residues from 1145 to 1311), we found a difference in our sequence from the sequence of the same region reported by Raychowdhury et al. (1989) . A stretch of six amino acid residues (numbers 1189-1194 in Figure 2 , designated by * above the letters) in our sequence substitutes for another stretch of 15 amino acid residues in the sequence reported by Raychowdhury et al. (1989) . Also, scattered throughout the sequence are several I substitution is located within the putative internalization signal directing receptors to clathrin-coated pits. There is also a difference in the length of cytoplasmic tails of gp330. Unfortunately, Raychowdhury et al. (1989) did not present the amino acid sequence of the C-terminal cytoplasmic tail, but stated that it was 188 amino acid residues long. In the primary structure obtained by us, the length of the cytoplasmic tail is 213 amino acid residues, i.e. considerably longer. Taking all these differences into account, we conclude that we have cloned and sequenced another molecular form of gp330, which is different in primary structure from the previously reported gp330, providing direct evidence for the existence of at least two forms of gp330.
Previously, using antibodies against the extracellular domain and against a peptide deduced to be in the cytoplasmic domain, Bachinsky et al. (1993) showed that, immuno-ultrastructurally, the anti-(cytoplasmic peptide) antibody reacted only with structural components at the base of microvilli of proximal renal tubular cells, whereas the anti-(ecto-domain) antibody reacted with components at both the base and the surface of microvilli .   60  120  180  240  300  360  420  480  540  600  660  720  780  840  900  960  1020  1080  1140  1200  1260  1320  1380  1440  1500  1560  1620  1650 On the basis of these results, they proposed that there were two forms of gp330 on the cell surface. One form (gp330-I) is restricted to the base of microvilli and has a cytoplasmic domain, whereas the other form (gp330-II) is present over the base and surface of microvilli and lacks the cytoplasmic domain.
We found differences in primary structures in the C-terminal part of gp330, showing that our form (gp330-III) is different from gp330-I. It needs to be pointed out that, although there are differences in the primary structures of gp330-I and gp330-III, both share the same peptide (Figure 2 ) that was used to produce anti-(cytoplasmic peptide) antibody by Bachinsky et al. (1993) . Because ofthe differences in the primary structures ofcytoplasmic domains of gp330-I and gp330-III, it is possible that these two forms have different conformations in their cytoplasmic domains, and therefore anti-peptide antibody may react with gp330-I and not with gp330-III. In that case, in the experiments performed by Bachinsky et al. (1993) gp330-III could have behaved as gp330-II. A test of this possibility, however, will require sequencing the various forms of gp330.
Whether these forms are products ofdifferent genes, or whether they result from alternative splicing, needs to be studied. It is possible that the structure of the C-terminal cytoplasmic domain plays an important role in the cellular compartmentalization of gp330 and its functions.
